MX355159B - Complejos de lipoproteina y fabricacion y usos de los mismos. - Google Patents

Complejos de lipoproteina y fabricacion y usos de los mismos.

Info

Publication number
MX355159B
MX355159B MX2016011834A MX2016011834A MX355159B MX 355159 B MX355159 B MX 355159B MX 2016011834 A MX2016011834 A MX 2016011834A MX 2016011834 A MX2016011834 A MX 2016011834A MX 355159 B MX355159 B MX 355159B
Authority
MX
Mexico
Prior art keywords
lipoprotein complexes
manufacturing
lipoprotein
apolipoproteins
complexes
Prior art date
Application number
MX2016011834A
Other languages
English (en)
Inventor
Jean-Louis Dasseux
Daniela Carmen Oniciu
Rose Ackermann
Original Assignee
Cerenis Therapeutics Holding Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerenis Therapeutics Holding Sa filed Critical Cerenis Therapeutics Holding Sa
Publication of MX355159B publication Critical patent/MX355159B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/042—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a una composición, caracterizada porque comprende una población de complejos de lipoproteína, cada uno comprendiendo (a) una fracción de lípido que comprende por lo menos un lípido neutro y por lo menos un lípido cargado negativamente; (b) una fracción de apolipoproteína que consiste esencialmente de una Apolipoproteína A-I ("ApoA-I"), en donde (i) por lo menos 80% de la apolipoproteína en la composición está en forma de complejo:; (ii) por lo menos 80% del lípido en la composición está en forma de complejo; (iii) no más de 20% de los residuos de metionina en la apolipoproteína están oxidados; (iv) el tamaño de distribución de los complejos de lipoproteína es de por lo menos 85%, por lo menos 90%, por lo menos 95%, por lo menos 97% homogéneo, como se refleja por un solo pico en una cromatografía de penetración en gel, y (v) la población no contiene ningún detergente.
MX2016011834A 2011-02-07 2013-08-06 Complejos de lipoproteina y fabricacion y usos de los mismos. MX355159B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161440371P 2011-02-07 2011-02-07
US201161452630P 2011-03-14 2011-03-14
US201161487263P 2011-05-17 2011-05-17

Publications (1)

Publication Number Publication Date
MX355159B true MX355159B (es) 2018-04-06

Family

ID=45592833

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013009083A MX343907B (es) 2011-02-07 2012-02-06 Complejos de lipoproteina y fabricacion y usos de los mismos.
MX2016011834A MX355159B (es) 2011-02-07 2013-08-06 Complejos de lipoproteina y fabricacion y usos de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2013009083A MX343907B (es) 2011-02-07 2012-02-06 Complejos de lipoproteina y fabricacion y usos de los mismos.

Country Status (27)

Country Link
US (9) US20120232005A1 (es)
EP (4) EP2673296B1 (es)
JP (5) JP6219170B2 (es)
KR (1) KR20140053848A (es)
CN (4) CN105288589A (es)
AU (3) AU2012214672B2 (es)
CA (1) CA2826158A1 (es)
CY (2) CY1121317T1 (es)
DK (3) DK2767546T3 (es)
ES (3) ES2994009T3 (es)
HR (2) HRP20190138T1 (es)
HU (2) HUE042314T2 (es)
IL (1) IL227634B (es)
IN (1) IN2013DN07828A (es)
LT (2) LT2767546T (es)
MX (2) MX343907B (es)
PH (2) PH12013501644A1 (es)
PL (2) PL2673296T3 (es)
PT (2) PT2767546T (es)
RS (2) RS58243B1 (es)
RU (2) RU2627173C2 (es)
SG (2) SG192693A1 (es)
SI (2) SI2767546T1 (es)
SM (2) SMT201900045T1 (es)
TW (2) TW201240671A (es)
WO (1) WO2012109162A1 (es)
ZA (1) ZA201305628B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
ES2617977T3 (es) 2010-06-30 2017-06-20 Csl Limited Una formulación de lipoproteína de alta densidad reconstituida y método de producción de la misma
HUE042314T2 (hu) 2011-02-07 2019-06-28 Cerenis Therapeutics Holding Sa Lipoprotein komplexek és azok gyártása és alkalmazásai
US9125943B2 (en) 2012-11-02 2015-09-08 Csl Limited Reconstituted HDL formulation
JP2016509068A (ja) * 2013-02-28 2016-03-24 エイジェンシー・フォー・サイエンス，テクノロジー・アンド・リサーチ クロマチン欠損細胞培養採取物からの抗体のクロマトグラフィー精製
US9708354B2 (en) 2013-03-15 2017-07-18 Cerenis Therapeutics Holding Sa Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
EP3842443B1 (en) 2013-03-15 2025-02-19 Cerenis Therapeutics Holding SA Methods for the synthesis of sphingomyelins and dihydrosphingomyelins
NZ631126A (en) 2013-08-08 2018-06-29 Csl Ltd Contaminant removal method
EP2853259A1 (en) * 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
CA2947127A1 (en) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers
WO2016019333A1 (en) 2014-07-31 2016-02-04 Kinemed, Inc. The effect of phospholipid composition of reconstituted hdl on its cholesterol efflux and anti-inflammatory properties
KR101671580B1 (ko) * 2014-08-26 2016-11-02 영남대학교 산학협력단 미녹시딜 수용액 제조방법
US10307491B2 (en) 2015-01-30 2019-06-04 The Regents Of The University Of Michigan Liposomal particles comprising biological molecules and uses thereof
JP2018516847A (ja) 2015-03-25 2018-06-28 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 生体高分子薬を送達するための組成物及び方法
US11642419B2 (en) * 2015-03-25 2023-05-09 The Regents Of The University Of Michigan Compositions and methods for treating cardiovascular related disorders
US12257352B2 (en) 2016-06-20 2025-03-25 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
EP3490579B1 (en) 2016-07-27 2025-09-10 Hartis-Pharma SA Therapeutic combinations to treat red blood cell disorders
WO2018029505A1 (en) 2016-08-11 2018-02-15 Cerenis Therapeutics Holding Sa Cer-001 therapy for treating familial primary hypoalphalipoproteinemia
AU2018210980A1 (en) * 2017-01-23 2019-08-08 Hdl Therapeutics, Inc. Methods for treating cholesterol-related diseases
ES2681124B1 (es) 2017-03-08 2019-06-19 Fund Imdea Alimentacion Usos medicos de la apolipoproteina a y de activadores de la misma
ES2984286T3 (es) * 2017-08-10 2024-10-29 Abionyx Pharma Sa Apómeros
EP3668600B1 (en) 2017-08-10 2024-05-15 Abionyx Pharma SA Cargomers
US12220462B1 (en) 2018-02-13 2025-02-11 Abionyx Pharma Sa Complexes for delivery of cyclic dinucleotides
HRP20240584T1 (hr) * 2018-07-03 2024-07-19 Bristol-Myers Squibb Company Postupak proizvodnje rekombinantnih proteina
JP2020138941A (ja) * 2019-02-28 2020-09-03 国立研究開発法人理化学研究所 バイセル及びその利用
CN114746100B (zh) 2019-11-20 2024-10-25 万能溶剂有限公司 用于肝再生的血浆级分
US11484551B2 (en) 2019-11-20 2022-11-01 Alkahest, Inc. Method of treating liver failure with plasma fraction IV-4
JP2023509514A (ja) 2020-01-07 2023-03-08 クリールリー、 インコーポレーテッド 医用画像分析、診断、重症度分類、意思決定、および／または疾患追跡のためのシステム、方法、およびデバイス
US11969280B2 (en) 2020-01-07 2024-04-30 Cleerly, Inc. Systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking
US20220392065A1 (en) 2020-01-07 2022-12-08 Cleerly, Inc. Systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking
WO2021209808A1 (en) 2020-04-16 2021-10-21 Abionyx Pharma Sa Cer-001 therapy for treating kidney disease
MX2022012969A (es) 2020-04-16 2022-11-09 Abionyx Pharma Sa Metodos para el tratamiento de condiciones agudas usando complejos basados en proteinas de union a lipidos.
US11752163B2 (en) 2020-04-16 2023-09-12 Abionyx Pharma Sa CER-001 therapy for treating kidney disease
IL301769A (en) 2020-10-01 2023-05-01 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
EP4259280A4 (en) * 2020-12-11 2025-02-12 The Regents Of The University Of Michigan Compositions and methods for preventing, attenuating, and treating medical conditions with shdl nanoparticles
WO2022150631A1 (en) * 2021-01-08 2022-07-14 Hdl Therapeutics, Inc Systems and methods for reducing low attenuation plaque and/or plaque burden in patients
MX2023012223A (es) * 2021-04-15 2023-10-26 Abionyx Pharma Sa Uso de complejos a base de proteinas de union a lipidos en soluciones de conservacion de organos.
AU2022275694A1 (en) * 2021-05-19 2023-11-16 Alkahest, Inc. Blood plasma fractions for use in liver regeneration
US12406365B2 (en) 2022-03-10 2025-09-02 Cleerly, Inc. Systems, devices, and methods for non-invasive image-based plaque analysis and risk determination
US20250217981A1 (en) 2022-03-10 2025-07-03 Cleerly, Inc. Systems, methods, and devices for image-based plaque analysis and risk determination
US20250143657A1 (en) 2022-03-10 2025-05-08 Cleerly, Inc. Systems, devices, and methods for non-invasive image-based plaque analysis and risk determination
US12440180B2 (en) 2022-03-10 2025-10-14 Cleerly, Inc. Systems, devices, and methods for non-invasive image-based plaque analysis and risk determination
AU2023250345A1 (en) 2022-04-06 2024-11-14 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
CN119317440A (zh) 2022-04-06 2025-01-14 阿比奥尼克斯制药公司 使用基于脂质结合蛋白的复合物治疗白细胞增多、内皮功能障碍和心脏炎的方法
IL317448A (en) 2022-06-10 2025-02-01 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using complexes based on lipid-binding proteins
JP2025519606A (ja) 2022-06-10 2025-06-26 アビオニクス ファーマ エスエー 脂質結合タンパク質に基づく複合体を使用して急性状態を処置するための方法
AU2023298303A1 (en) 2022-06-28 2025-02-13 Abionyx Pharma Sa Compounds and processes for the synthesis of sphingomyelins
KR20240009061A (ko) * 2022-07-13 2024-01-22 (재)씨젠의료재단 혈청 내 다중 아포지단백질의 직접정량 방법
IL322074A (en) 2023-01-13 2025-09-01 Abionyx Pharma Sa Treatment using a lipid-binding protein molecule
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
AU587989B2 (en) 1984-10-16 1989-09-07 Mitsubishi Chemical Corporation DMA fragments, expression vectors, proteins, hosts, and process for production of the proteins
WO1986004144A1 (en) 1984-12-31 1986-07-17 International Genetic Engineering, Inc. Peptide fragments of human apolipoprotein, type-specific antibodies and methods of use
GB8625435D0 (en) 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
US5128318A (en) 1987-05-20 1992-07-07 The Rogosin Institute Reconstituted HDL particles and uses thereof
GB8712540D0 (en) 1987-05-28 1987-07-01 Ucb Sa Expression of human proapolipoprotein a-i
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
IT1229996B (it) 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
US5220043A (en) 1991-03-21 1993-06-15 Ohio University Synthesis of D-erythro-sphingomyelins
WO1993000443A1 (en) 1991-06-26 1993-01-07 Bio-Technology General Corp. Purification of recombinant apolipoprotein e from bacteria
US5408038A (en) 1991-10-09 1995-04-18 The Scripps Research Institute Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides
SE9103701D0 (sv) 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
AU5457294A (en) 1992-10-29 1994-05-24 Board Of Regents, The University Of Texas System Adenovirus-mediated ldl receptor gene transfer and targeting
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
SE9203753D0 (sv) 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
US5874075A (en) * 1993-10-06 1999-02-23 Amgen Inc. Stable protein: phospholipid compositions and methods
US5643757A (en) 1994-03-21 1997-07-01 American Cyanamid Company High yield production of human apolipoprotein A1 in E. coli.
CA2185450A1 (en) 1994-03-22 1995-09-28 Patrick Tso Eating suppressant peptides
IL109558A (en) 1994-05-04 2004-08-31 Yissum Res Dev Co DNA structures Derived from the SV40 virus that include DNA sequences External
US5932536A (en) 1994-06-14 1999-08-03 The Rockefeller University Compositions for neutralization of lipopolysaccharides
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
FR2734568B1 (fr) 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
US6258596B1 (en) 1995-05-22 2001-07-10 Aventis Pharmaceuticals Products Inc. Variants of apolipoprotein A-I
SE9603068D0 (sv) 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
US6306433B1 (en) 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
GB9919713D0 (en) 1999-08-19 1999-10-20 Queen Mary & Westfield College New medical use of high density lipoprotein
EP1210411B1 (en) 1999-08-25 2006-10-18 Immunex Corporation Compositions and methods for improved cell culture
KR100545945B1 (ko) 2000-07-03 2006-01-25 갈라 디자인, 인크. 발현 벡터
US20040235173A1 (en) 2000-07-03 2004-11-25 Gala Design, Inc. Production of host cells containing multiple integrating vectors by serial transduction
US20030224415A1 (en) 2001-06-29 2003-12-04 Gala Design, Inc. Selection free growth of host cells containing multiple integrating vectors
CA2413151C (en) 2000-07-03 2012-11-27 Gala Design, Inc. Host cells containing multiple integrating vectors
AU2001271614B2 (en) 2000-07-03 2007-05-31 Catalent Pharma Solutions, Llc Host cells containing multiple integrating vectors
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7148197B2 (en) 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
BR0115257A (pt) * 2000-11-10 2003-08-12 Proteopharma Aps Análogos de apolipoproteìna
DK1345959T3 (da) 2000-11-20 2011-09-05 Univ Illinois Membranscaffoldproteiner
IL157446A0 (en) 2001-02-23 2004-03-28 Immunex Corp Immunex Corp Increased recovery of active proteins
US7217785B2 (en) 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
DE60226881D1 (de) 2001-08-20 2008-07-10 Zlb Bioplasma Ag High-density -lipoprotein zur behandlung von schlaganfällen und ischämiezuständen
US7223726B2 (en) 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
JP2006507223A (ja) * 2002-05-17 2006-03-02 エスペリオン セラピューティクス，インコーポレイテッド 脂質代謝異常疾患の治療方法
EP1545576A2 (en) 2002-07-30 2005-06-29 Esperion Therapeutics Inc. Methods of using non-human animal apoliprotein a-i protein
EP1585504A4 (en) * 2002-11-06 2009-07-15 Azaya Therapeutics Inc Protein stabilized liposomal formulations of pharmaceutical active ingredients
CA2531227A1 (en) 2003-07-03 2005-02-10 Lipid Sciences Inc. Methods and apparatus for creating particle derivatives of hdl with reduced lipid content
PE20050438A1 (es) * 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
KR100560102B1 (ko) 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
KR101185609B1 (ko) * 2004-07-16 2012-09-24 트러스티즈 오브 터프츠 칼리지 아포리포단백질 ａ１ 미메틱 및 이의 용도
WO2006012632A2 (en) 2004-07-23 2006-02-02 Xencor, Inc. Apolipoprotein a-1 derivatives with altered immunogenicity
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
EP1917278A2 (en) * 2005-08-26 2008-05-07 Cerenis Therapeutics Holding SA Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria
US8541236B2 (en) * 2006-12-08 2013-09-24 University Of Washington Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
US20080293102A1 (en) 2007-02-28 2008-11-27 Cerenis Therapeutics Holding, S.A. Compositions and methods for producing apolipoprotein
WO2008141230A1 (en) * 2007-05-09 2008-11-20 Lawrence Livermore National Security, Llc Methods and systems for monitoring production of a target protein in a nanolipoprotein particle
CA2694854C (en) 2007-08-17 2016-09-27 Csl Behring Gmbh Methods for purification of alpha-1-antitrypsin and apolipoprotein a-i
US9173890B2 (en) * 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
WO2009055538A1 (en) * 2007-10-23 2009-04-30 The Cleveland Clinic Foundation Oxidant resistant apolipoprotein a-1 and mimetic peptides
US20110293557A1 (en) 2008-06-13 2011-12-01 Proyecto De Biomedicina Cima, S.L. Conjugates for the administration of biologically active compounds
JP5719783B2 (ja) 2009-02-16 2015-05-20 セレニス セラピューティクス ホールディング エスアー アポリポタンパクａ−ｉ模倣物
US10525152B2 (en) * 2009-10-09 2020-01-07 Signablok, Inc. Methods and compositions for targeted imaging
US8987444B2 (en) 2010-01-18 2015-03-24 Msn Laboratories Private Limited Process for the preparation of amide intermediates and their use thereof
HUE042314T2 (hu) 2011-02-07 2019-06-28 Cerenis Therapeutics Holding Sa Lipoprotein komplexek és azok gyártása és alkalmazásai
AU2012236889A1 (en) * 2011-03-25 2013-05-09 The Trustees Of Columbia University In The City Of New York Pegylated human HDL particle and process for production thereof

Also Published As

Publication number Publication date
KR20140053848A (ko) 2014-05-08
US20160095901A1 (en) 2016-04-07
RU2627173C2 (ru) 2017-08-03
CY1121317T1 (el) 2020-05-29
AU2015271986B2 (en) 2018-02-22
PL2673296T3 (pl) 2019-03-29
HRP20190138T1 (hr) 2019-03-22
NZ613524A (en) 2015-10-30
US11376309B2 (en) 2022-07-05
US12364735B2 (en) 2025-07-22
US20240000887A1 (en) 2024-01-04
AU2012214672B2 (en) 2015-10-01
DK2673296T3 (en) 2019-02-18
EP2767546A1 (en) 2014-08-20
AU2012214672A1 (en) 2013-05-02
HK1198834A1 (en) 2015-06-12
MX2013009083A (es) 2014-02-03
JP2018076286A (ja) 2018-05-17
MX343907B (es) 2016-11-28
HUE042314T2 (hu) 2019-06-28
SG10201801372YA (en) 2018-04-27
US20250302916A1 (en) 2025-10-02
US9187551B2 (en) 2015-11-17
HUE041797T2 (hu) 2019-05-28
CN107337728A (zh) 2017-11-10
PH12016500191A1 (en) 2017-10-18
JP6720126B2 (ja) 2020-07-08
DK3466969T3 (da) 2024-07-22
US11998587B2 (en) 2024-06-04
RU2017126088A (ru) 2019-01-31
US20150152164A1 (en) 2015-06-04
US20140213501A1 (en) 2014-07-31
SMT201900045T1 (it) 2019-02-28
CN105294859A (zh) 2016-02-03
EP2673296A1 (en) 2013-12-18
ZA201305628B (en) 2014-04-30
JP2022050603A (ja) 2022-03-30
HRP20190072T1 (hr) 2019-03-08
EP2767546B1 (en) 2018-10-17
JP2020176122A (ja) 2020-10-29
RS58275B1 (sr) 2019-03-29
US10328119B2 (en) 2019-06-25
CN103443123B (zh) 2020-05-29
JP7009559B2 (ja) 2022-01-25
CA2826158A1 (en) 2012-08-16
CN105288589A (zh) 2016-02-03
SI2767546T1 (sl) 2019-03-29
CN103443123A (zh) 2013-12-11
CY1121318T1 (el) 2020-05-29
IN2013DN07828A (es) 2015-07-03
TW201737935A (zh) 2017-11-01
LT2767546T (lt) 2019-02-25
ES2716349T3 (es) 2019-06-12
JP6219170B2 (ja) 2017-10-25
AU2018203258B9 (en) 2021-01-07
JP2014506884A (ja) 2014-03-20
PT2673296T (pt) 2019-01-31
TW201240671A (en) 2012-10-16
US20230372441A1 (en) 2023-11-23
PL2767546T3 (pl) 2019-04-30
US20120232005A1 (en) 2012-09-13
PT2767546T (pt) 2019-01-28
PH12013501644A1 (en) 2013-10-14
JP2024170492A (ja) 2024-12-10
SMT201900194T1 (it) 2019-05-10
AU2018203258B2 (en) 2020-12-10
EP3466969B1 (en) 2024-05-08
IL227634A0 (en) 2013-09-30
LT2673296T (lt) 2019-02-25
EP2673296B1 (en) 2018-10-24
CN107337728B (zh) 2023-05-23
IL227634B (en) 2020-05-31
RS58243B1 (sr) 2019-03-29
DK2767546T3 (en) 2019-02-04
AU2018203258A1 (en) 2018-05-31
SI2673296T1 (sl) 2019-03-29
US20190298800A1 (en) 2019-10-03
EP4400511A3 (en) 2024-09-04
EP4400511A2 (en) 2024-07-17
ES2994009T3 (en) 2025-01-15
RU2013139066A (ru) 2015-03-20
EP3466969A1 (en) 2019-04-10
AU2015271986A1 (en) 2016-01-21
US10322163B2 (en) 2019-06-18
US20220362336A1 (en) 2022-11-17
WO2012109162A1 (en) 2012-08-16
US11969456B2 (en) 2024-04-30
ES2717455T3 (es) 2019-06-21
SG192693A1 (en) 2013-09-30

Similar Documents

Publication Publication Date Title
PH12016500191A1 (en) Lipoprotein complexes and manufacturing and uses thereof
JO3199B1 (ar) مركبات 5- فلورو-1h- بيرازولوبيريدينات مستبدلة واستخدامها
UA115887C2 (uk) АМІНОЗАМІЩЕНІ ІМІДАЗО[1,2-а]ПІРИДИНКАРБОКСАМІДИ І ЇХ ЗАСТОСУВАННЯ
MY156777A (en) Substituted 2-acetamido-5-ary1-1,2,4-triazolones and use thereof
EA201170465A1 (ru) Способы лечения прогрессирующего множественного склероза
PH12014501595A1 (en) Substituted annulated pyrimidines and triazines, and use thereof
PH12014502496B1 (en) Bicyclically substituted uracils and the use thereof
PH12014500460A1 (en) Substituted annellated pyrimidine and the use thereof
MX2013011691A (es) Inhibidores de la replicacion viral, su proceso de preparacion y sus usos terapeuticos.
PH12016500065A1 (en) Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof
BR112013022052A2 (pt) ligantes antagonísticos de dr3
MX362271B (es) Nueva forma cristalina de ciclosporina a, metodos de preparacion y metodos para su uso.
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
PH12016500608A1 (en) Cyclic thienouracil-carboxamides and use thereof
PH12012500897A1 (en) Novel arylated camphenes, processes for their preparation and uses thereof
UA111520C2 (uk) [1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази
MX2013002261A (es) N-fenetiltriazolonacetamidas sustituidas y su uso.
UA114486C2 (uk) Застосування 4-амінопіридину у лікуванні пов'язаної з інсультом сенсорно-рухової недостатності
WO2013074816A3 (en) Novel inhibitors of nox1
MX2013012967A (es) Composicion de miel con l-alanil-l-glutamina.
PH12014500577A1 (en) Sulfonic acid salts of heterocyclylamide-substituted imidazoles
HK1202868A1 (en) Carboxamide-substituted heteroaryl-pyrazoles and the use thereof
TN2013000243A1 (en) Substituted 1-benzylcycloalkylcarboxlic acids and use thereof